Say Hello!
Don’t be shy.

 
0333 323 1843
 

[email protected]

 

BioCity Group HQ:
Pennyfoot Street
Nottingham
NG1 1GF

MHRA Inspection success for Nottingham’s Upperton Pharma Solutions

MHRA Inspection success for Nottingham’s Upperton Pharma Solutions

Upperton Pharma Solutions’ new pharmaceutical manufacturing facilities at Nottingham Science and Technology Park have successfully passed inspection by the UK Medicines and Healthcare products Regulatory Agency (MHRA).

A pharmaceutical contract development and manufacturing organisation (CDMO), Upperton Pharma Solutions moved to its new facilities on Nottingham Science and Technology Park from its previous headquarters at BioCity Nottingham in March 2018, as part of a planned expansion of its services.

The company has invested heavily in the new facilities both in terms of building enhancements and in the expansion of its processing and analytical capabilities.

The successful MHRA inspection provides Upperton Pharma Solutions with the necessary MHRA licenses for manufacture, downstream processing into capsules and tablets, as well as release of spray dried formulations of Biotherapeutics and small molecule APIs for clinical trials.

The company is also able to now develop pharmaceutical formulations for oral, nasal and pulmonary delivery right through from early feasibility studies to Phases I & II clinical manufacture, all from its Nottingham Science and Technology Park site.

Richard Johnson, CEO and Founder of Upperton Pharma Solutions, said: “We are absolutely delighted with the expansion of our capabilities in GMP clinical manufacturing and look forward to seeing our clients’ projects progress within Upperton, from early formulation development studies right through to clinical manufacture.

“The positive endorsement by the MHRA will enable a seamless transition from R&D to GMP manufacture within the organisation, ensuring that all of the project-specific knowledge and expertise developed in R&D will flow through to inform the GMP manufacturing processes.”

Paul Kelsall, Director of Clinical Trials Manufacturing commented: “This is a great opportunity for our business and is a result of our team’s commitment to achieve the targets and aspirations of our business. We are looking forward to working with our clients and offering services from early stage development through to clinical manufacture. These are exciting times for Upperton as we continue to move forward and expand our capabilities.”

To read more about Upperton Pharma Solutions’ GMP capabilities, click here